International Journal Of Creative and Innovative Research In All Studies
International Peer-Reviewed Journal

 >   Manuscript Details

Manuscript Details - IJCIRAS1491

ManuScript Details
Paper Id: IJCIRAS1491
Title: EFFICACY AND SAFETY OF TRASTUZUMAB IN COMBINATION TO ORAL VINORELBINE IN METASTATIC BREAST CANCER OVER EXPRESSED HER2 : A RETROSPECTIVE STUDY
Published in: International Journal Of Creative and Innovative Research In All Studies
Publisher: IJCIRAS
ISSN: 2581-5334
Volume / Issue: Volume 2 Issue 8
Pages: 1
Published On: 1/27/2020 11:38:28 PM      (MM/dd/yyyy)
Main Author Details
Name: Kheira REKAI
Institute: Establishment university hospital of Oran
Co - Author Details
Author Name Author Institute
Terki Khadidja Establishment university hospital of Oran
Abstract
Research Area: Oncology
KeyWord: Metastatic Breast cancer HER + , Trastuzumab , vinorelbine
Abstract: Introduction : chemotherapy plus trastuzumab (H) is the standard first line treatment for HER2-positive MBC . Trastuzumab plus vinorelbine regimen is among the most active and well-tolerated options in this setting. The all-oral chemotherapy combination has shown activity and good tolerance in MBC. The aim of our study is to analyze the epidemiological and clinical data ; and to evaluate effectiveness safety and tolerance of trastuzumab plus oral vinorelbine in MBC HER2+ . Methods: we retrospectively reviewed all patients with HER2+ MBC who received oral vinorelbine with trastuzumab at our institution between January 2016 and March 2019 . Vinorelbine was given as a 80mg/m² dose(following a first cycle at 60mg/m² D1&D8 every 3weeks,trastuzumab at 8mg/kg on D1 (loading dose) then 6mg/kg iv every 3weeks. Results: we identified 66 patients treated from January 2016 to March 2019 . Median age was 43 years (32-75) (60%≤50Y). All patients had invasive ductal histology. All tumours were HER2+ by immunohistochemistry and 65% were HR negative. Other patients characteristics were: prior (neo)adjuvant CT 80%;prior trastuzumab 55%; visceral involvement 65% ; ≥2 metastatic sites 50%; median number of vinorelbine administrations 17 (range 9-32); 65% of patients received more than 6cycles. Adverse events: G1/2: neutropenia 25%, vomiting 15%, asthenia 10% and LVEF decline 10%. Efficacy: objective response rate 80%, CR15%, PR 35%, SD 30%, PD 20%. Median progression-free survival was 12 months (2, 5- 34 months) Conclusion: The oral regimen of vinorelbine with trastuzumab has shown high anti-tumoral efficacy in pts with HER2-positive MBC. Toxicity profile was acceptable, with in particular, a very low rate of alopecia. Full treatment could be maintained until progression of the disease in the majority of patients.
Citations
Copy and paste a formatted citation or use one of the links to import into a bibliography manager and reference.

IEEE
Kheira REKAI, Terki Khadidja, "Efficacy and safety of trastuzumab in combination to oral vinorelbine in metastatic breast cancer over expressed HER2 : A retrospective study", International Journal Of Creative and Innovative Research In All Studies, vol. 2, no. 8, pp. 44-44, 2020.
MLA Kheira REKAI, Terki Khadidja "Efficacy and safety of trastuzumab in combination to oral vinorelbine in metastatic breast cancer over expressed HER2 : A retrospective study." International Journal Of Creative and Innovative Research In All Studies, vol 2, no. 8, 2020, pp. 44-44.
APA Kheira REKAI, Terki Khadidja (2020). Efficacy and safety of trastuzumab in combination to oral vinorelbine in metastatic breast cancer over expressed HER2 : A retrospective study. International Journal Of Creative and Innovative Research In All Studies, 2(8), 44-44.
Efficacy and safety of trastuzumab in combination to oral vinorelbine in metastatic breast cancer over expressed HER2 : A retrospective study
Number Of Downloads - 3


Last downloaded on 15/06/2020
Similar-Paper
Manuscript

Need Some Help?

Feel free to visit our FAQ section. You can also send us an email here or give us a call on +91 9898652593, +91 70165 51209.